| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 128 | 2024 | 330 | 28.630 |
Why?
|
| Dexamethasone | 57 | 2024 | 344 | 8.340 |
Why?
|
| Oligopeptides | 38 | 2024 | 188 | 7.990 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 66 | 2024 | 2552 | 7.720 |
Why?
|
| Bortezomib | 38 | 2024 | 82 | 3.550 |
Why?
|
| Neoplasm, Residual | 9 | 2024 | 181 | 3.070 |
Why?
|
| Antibodies, Monoclonal | 22 | 2024 | 1400 | 2.930 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 13 | 2023 | 889 | 2.930 |
Why?
|
| Thalidomide | 20 | 2024 | 57 | 2.610 |
Why?
|
| Boronic Acids | 18 | 2015 | 56 | 2.120 |
Why?
|
| Pyrazines | 18 | 2015 | 94 | 2.050 |
Why?
|
| Proteasome Inhibitors | 15 | 2023 | 52 | 1.780 |
Why?
|
| Antineoplastic Agents | 22 | 2020 | 2411 | 1.730 |
Why?
|
| Hydrazines | 5 | 2020 | 31 | 1.620 |
Why?
|
| Triazoles | 5 | 2020 | 102 | 1.540 |
Why?
|
| Antibodies, Monoclonal, Humanized | 6 | 2022 | 967 | 1.470 |
Why?
|
| Drug Resistance, Neoplasm | 19 | 2020 | 616 | 1.430 |
Why?
|
| Recurrence | 27 | 2021 | 1140 | 1.360 |
Why?
|
| Humans | 140 | 2024 | 89063 | 1.330 |
Why?
|
| Aged | 67 | 2024 | 19077 | 1.330 |
Why?
|
| Transplantation, Autologous | 15 | 2023 | 343 | 1.260 |
Why?
|
| Middle Aged | 69 | 2024 | 25863 | 1.180 |
Why?
|
| Treatment Outcome | 42 | 2024 | 8203 | 1.130 |
Why?
|
| Male | 94 | 2024 | 42251 | 1.080 |
Why?
|
| Cost-Benefit Analysis | 3 | 2018 | 461 | 1.080 |
Why?
|
| Neoplasm Recurrence, Local | 13 | 2023 | 1363 | 1.030 |
Why?
|
| Female | 77 | 2024 | 46011 | 0.990 |
Why?
|
| Adult | 54 | 2024 | 26507 | 0.920 |
Why?
|
| Stem Cell Transplantation | 8 | 2021 | 188 | 0.880 |
Why?
|
| Salvage Therapy | 6 | 2020 | 235 | 0.800 |
Why?
|
| Cell- and Tissue-Based Therapy | 3 | 2022 | 51 | 0.790 |
Why?
|
| Aged, 80 and over | 30 | 2024 | 6777 | 0.770 |
Why?
|
| Quality of Life | 12 | 2024 | 1662 | 0.770 |
Why?
|
| Melphalan | 7 | 2022 | 98 | 0.760 |
Why?
|
| Corneal Diseases | 1 | 2021 | 33 | 0.750 |
Why?
|
| Doxorubicin | 6 | 2017 | 298 | 0.710 |
Why?
|
| Thiophenes | 1 | 2019 | 43 | 0.690 |
Why?
|
| Quinolones | 1 | 2019 | 60 | 0.670 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2019 | 102 | 0.660 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 195 | 0.640 |
Why?
|
| Drug Administration Schedule | 12 | 2021 | 894 | 0.640 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 280 | 0.640 |
Why?
|
| Plasma Cells | 2 | 2016 | 84 | 0.620 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2024 | 189 | 0.610 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 604 | 0.610 |
Why?
|
| Disease-Free Survival | 13 | 2020 | 1214 | 0.590 |
Why?
|
| Apoptosis | 6 | 2019 | 1716 | 0.570 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2020 | 859 | 0.560 |
Why?
|
| Maintenance Chemotherapy | 5 | 2024 | 84 | 0.550 |
Why?
|
| Caspase 10 | 1 | 2015 | 5 | 0.540 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2022 | 91 | 0.530 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 531 | 0.510 |
Why?
|
| Immunoglobulin Light Chains | 2 | 2015 | 89 | 0.500 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 643 | 0.500 |
Why?
|
| Prednisone | 5 | 2021 | 258 | 0.500 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 599 | 0.490 |
Why?
|
| Chromosome Aberrations | 3 | 2024 | 390 | 0.490 |
Why?
|
| Myeloma Proteins | 2 | 2024 | 35 | 0.450 |
Why?
|
| Follicle Stimulating Hormone | 11 | 1997 | 147 | 0.440 |
Why?
|
| Retreatment | 5 | 2019 | 108 | 0.430 |
Why?
|
| Survival Analysis | 8 | 2019 | 1533 | 0.430 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2024 | 192 | 0.430 |
Why?
|
| Prognosis | 13 | 2023 | 3773 | 0.420 |
Why?
|
| Physicians | 1 | 2020 | 689 | 0.420 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2018 | 1940 | 0.420 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2023 | 28 | 0.420 |
Why?
|
| Clinical Trials as Topic | 7 | 2020 | 1149 | 0.410 |
Why?
|
| Geriatric Assessment | 3 | 2024 | 182 | 0.410 |
Why?
|
| Inhibins | 6 | 1992 | 37 | 0.400 |
Why?
|
| Sertoli Cells | 11 | 1992 | 18 | 0.400 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 705 | 0.360 |
Why?
|
| B-Cell Maturation Antigen | 4 | 2023 | 4 | 0.360 |
Why?
|
| Disease Management | 3 | 2021 | 329 | 0.350 |
Why?
|
| Pituitary Gland | 6 | 1997 | 119 | 0.340 |
Why?
|
| Immunologic Factors | 4 | 2022 | 171 | 0.330 |
Why?
|
| Drug Synergism | 3 | 2019 | 306 | 0.330 |
Why?
|
| Patient Care Team | 2 | 2021 | 283 | 0.300 |
Why?
|
| Anemia | 2 | 2023 | 129 | 0.300 |
Why?
|
| Neoplasm Staging | 6 | 2019 | 2001 | 0.300 |
Why?
|
| Models, Economic | 2 | 2017 | 62 | 0.280 |
Why?
|
| Protease Inhibitors | 4 | 2012 | 73 | 0.280 |
Why?
|
| United States | 7 | 2021 | 6955 | 0.280 |
Why?
|
| Thrombocytopenia | 3 | 2023 | 187 | 0.270 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2017 | 142 | 0.270 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 470 | 0.270 |
Why?
|
| Disease Progression | 5 | 2024 | 1488 | 0.270 |
Why?
|
| Smoldering Multiple Myeloma | 2 | 2022 | 3 | 0.260 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 3657 | 0.260 |
Why?
|
| Polyethylene Glycols | 3 | 2015 | 358 | 0.260 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2022 | 172 | 0.240 |
Why?
|
| Cell Line, Tumor | 4 | 2019 | 2552 | 0.240 |
Why?
|
| Premedication | 1 | 2024 | 58 | 0.240 |
Why?
|
| Mass Spectrometry | 1 | 2024 | 193 | 0.230 |
Why?
|
| Withholding Treatment | 1 | 2024 | 117 | 0.230 |
Why?
|
| Luteinizing Hormone | 6 | 1997 | 167 | 0.220 |
Why?
|
| Gonadotropin-Releasing Hormone | 4 | 1997 | 108 | 0.220 |
Why?
|
| DNA Copy Number Variations | 1 | 2024 | 177 | 0.220 |
Why?
|
| Medical Oncology | 2 | 2020 | 382 | 0.220 |
Why?
|
| Heterocyclic Compounds | 1 | 2022 | 17 | 0.220 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2000 | 133 | 0.220 |
Why?
|
| Imides | 1 | 2022 | 26 | 0.210 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2022 | 8 | 0.210 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 154 | 0.200 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2022 | 155 | 0.190 |
Why?
|
| Time Factors | 9 | 2020 | 5320 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 83 | 0.190 |
Why?
|
| Maximum Tolerated Dose | 4 | 2016 | 272 | 0.190 |
Why?
|
| Cornea | 1 | 2021 | 70 | 0.190 |
Why?
|
| Autografts | 1 | 2020 | 28 | 0.190 |
Why?
|
| Jehovah's Witnesses | 1 | 2021 | 20 | 0.190 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2021 | 75 | 0.190 |
Why?
|
| Thiadiazoles | 2 | 2017 | 12 | 0.180 |
Why?
|
| Intention | 1 | 2020 | 51 | 0.180 |
Why?
|
| Bone Marrow Examination | 1 | 2020 | 47 | 0.180 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family | 1 | 2020 | 15 | 0.180 |
Why?
|
| Pharmacists | 1 | 2020 | 32 | 0.180 |
Why?
|
| Animals | 22 | 2019 | 27317 | 0.170 |
Why?
|
| Primary Cell Culture | 1 | 2019 | 76 | 0.170 |
Why?
|
| Biomarkers | 5 | 2022 | 1755 | 0.170 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2019 | 66 | 0.170 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2019 | 11 | 0.170 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 93 | 0.170 |
Why?
|
| Health Care Surveys | 1 | 2020 | 280 | 0.170 |
Why?
|
| Cytogenetic Analysis | 1 | 2019 | 71 | 0.170 |
Why?
|
| Cycloheximide | 2 | 1989 | 56 | 0.170 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 342 | 0.160 |
Why?
|
| Immunoconjugates | 1 | 2020 | 110 | 0.160 |
Why?
|
| Fatigue | 5 | 2022 | 179 | 0.160 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 130 | 0.160 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 2014 | 0.160 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2019 | 207 | 0.160 |
Why?
|
| Transforming Growth Factor beta | 1 | 2000 | 321 | 0.160 |
Why?
|
| Gene Expression Profiling | 3 | 2024 | 1429 | 0.160 |
Why?
|
| Flow Cytometry | 1 | 2020 | 691 | 0.160 |
Why?
|
| Karyopherins | 1 | 2018 | 15 | 0.150 |
Why?
|
| Cells, Cultured | 15 | 2016 | 2880 | 0.150 |
Why?
|
| Leukemia | 1 | 2000 | 323 | 0.150 |
Why?
|
| Benzeneacetamides | 1 | 2017 | 11 | 0.150 |
Why?
|
| Glutaminase | 1 | 2017 | 12 | 0.150 |
Why?
|
| Mice | 5 | 2019 | 11737 | 0.150 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2018 | 122 | 0.150 |
Why?
|
| Preoperative Care | 1 | 2019 | 396 | 0.150 |
Why?
|
| Survival Rate | 4 | 2017 | 1889 | 0.140 |
Why?
|
| Drug Costs | 1 | 2017 | 63 | 0.140 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2020 | 306 | 0.140 |
Why?
|
| Proteomics | 2 | 2016 | 230 | 0.140 |
Why?
|
| Testosterone | 6 | 1993 | 275 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 481 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2017 | 354 | 0.140 |
Why?
|
| Naphthyridines | 1 | 2016 | 27 | 0.140 |
Why?
|
| Lactones | 1 | 2016 | 27 | 0.140 |
Why?
|
| Proteome | 1 | 2017 | 132 | 0.130 |
Why?
|
| Caspase 8 | 1 | 2015 | 34 | 0.130 |
Why?
|
| Intracellular Space | 1 | 2015 | 38 | 0.130 |
Why?
|
| Cyclopentanes | 1 | 2015 | 27 | 0.130 |
Why?
|
| Ubiquitins | 1 | 2015 | 38 | 0.130 |
Why?
|
| Genetic Testing | 1 | 2000 | 537 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 2 | 2015 | 285 | 0.130 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 2612 | 0.130 |
Why?
|
| Combined Modality Therapy | 3 | 2020 | 1710 | 0.130 |
Why?
|
| Phosphorylcholine | 2 | 2012 | 28 | 0.130 |
Why?
|
| Transcription Factors | 2 | 2000 | 1652 | 0.130 |
Why?
|
| Cyanoacrylates | 1 | 2015 | 5 | 0.130 |
Why?
|
| Precision Medicine | 2 | 2021 | 410 | 0.130 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2015 | 37 | 0.120 |
Why?
|
| Pyrroles | 1 | 2016 | 187 | 0.120 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2015 | 65 | 0.120 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 161 | 0.120 |
Why?
|
| Biomedical Research | 2 | 2010 | 398 | 0.120 |
Why?
|
| Boron Compounds | 1 | 2014 | 20 | 0.120 |
Why?
|
| Prospective Studies | 4 | 2023 | 4273 | 0.120 |
Why?
|
| Enzyme Activation | 1 | 2015 | 698 | 0.120 |
Why?
|
| Remission Induction | 2 | 2013 | 740 | 0.120 |
Why?
|
| Glycine | 1 | 2014 | 94 | 0.120 |
Why?
|
| Lymphoma | 1 | 2015 | 265 | 0.120 |
Why?
|
| Rats | 16 | 1997 | 4040 | 0.110 |
Why?
|
| Biomarkers, Tumor | 3 | 2017 | 1543 | 0.110 |
Why?
|
| Autophagy | 1 | 2015 | 159 | 0.110 |
Why?
|
| Transferrin | 4 | 1990 | 19 | 0.110 |
Why?
|
| Drug Approval | 1 | 2014 | 66 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2024 | 1265 | 0.110 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 434 | 0.110 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 848 | 0.110 |
Why?
|
| Pyridines | 1 | 2015 | 315 | 0.110 |
Why?
|
| Pyrimidines | 1 | 2015 | 372 | 0.110 |
Why?
|
| Hypophosphatemia | 1 | 2012 | 7 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2012 | 14 | 0.100 |
Why?
|
| Gonadotropins | 1 | 1991 | 34 | 0.100 |
Why?
|
| Secondary Prevention | 1 | 2012 | 158 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 645 | 0.100 |
Why?
|
| Drug Therapy, Combination | 4 | 2019 | 783 | 0.100 |
Why?
|
| Signal Transduction | 2 | 2011 | 3373 | 0.100 |
Why?
|
| Alkaline Phosphatase | 1 | 2011 | 132 | 0.100 |
Why?
|
| Hyperglycemia | 1 | 2012 | 172 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2011 | 116 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 340 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2011 | 156 | 0.090 |
Why?
|
| Authorship | 1 | 2010 | 23 | 0.090 |
Why?
|
| Sirolimus | 1 | 2011 | 170 | 0.090 |
Why?
|
| Rats, Inbred Strains | 8 | 1992 | 312 | 0.090 |
Why?
|
| Conflict of Interest | 1 | 2010 | 68 | 0.080 |
Why?
|
| Drug Industry | 1 | 2010 | 54 | 0.080 |
Why?
|
| Disclosure | 1 | 2010 | 110 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 2362 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2020 | 865 | 0.080 |
Why?
|
| Cohort Studies | 4 | 2020 | 2863 | 0.080 |
Why?
|
| Periodicals as Topic | 1 | 2010 | 168 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2011 | 575 | 0.070 |
Why?
|
| Mutation | 3 | 2021 | 4132 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2007 | 126 | 0.070 |
Why?
|
| Neoplasms | 1 | 2022 | 3035 | 0.070 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 157 | 0.070 |
Why?
|
| Risk Factors | 2 | 2016 | 5466 | 0.070 |
Why?
|
| RNA, Messenger | 4 | 2007 | 2011 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2007 | 196 | 0.070 |
Why?
|
| Intention to Treat Analysis | 2 | 2017 | 69 | 0.070 |
Why?
|
| T-Lymphocytes | 2 | 2023 | 1223 | 0.070 |
Why?
|
| Patient Selection | 2 | 2020 | 682 | 0.070 |
Why?
|
| Testis | 3 | 1992 | 152 | 0.070 |
Why?
|
| Genome, Human | 1 | 2011 | 767 | 0.070 |
Why?
|
| Intercellular Junctions | 4 | 1992 | 68 | 0.070 |
Why?
|
| Nausea | 2 | 2020 | 176 | 0.070 |
Why?
|
| Receptors, LHRH | 2 | 1997 | 4 | 0.070 |
Why?
|
| Canada | 2 | 2016 | 208 | 0.060 |
Why?
|
| Pain | 2 | 2022 | 400 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2018 | 682 | 0.060 |
Why?
|
| Injections, Subcutaneous | 1 | 2024 | 125 | 0.060 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2024 | 22 | 0.060 |
Why?
|
| RUNX1 Translocation Partner 1 Protein | 2 | 2000 | 8 | 0.060 |
Why?
|
| Whole Genome Sequencing | 1 | 2024 | 87 | 0.060 |
Why?
|
| 3T3 Cells | 2 | 2000 | 97 | 0.060 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 2 | 2000 | 57 | 0.060 |
Why?
|
| Melanoma | 1 | 2007 | 467 | 0.060 |
Why?
|
| Cell Transplantation | 1 | 2023 | 47 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2022 | 50 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2007 | 579 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 142 | 0.050 |
Why?
|
| Adrenal Insufficiency | 1 | 2022 | 23 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2022 | 166 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 55 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2023 | 308 | 0.050 |
Why?
|
| Cladribine | 1 | 2002 | 35 | 0.050 |
Why?
|
| Induction Chemotherapy | 1 | 2022 | 151 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2022 | 171 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2022 | 299 | 0.050 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2002 | 186 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2022 | 178 | 0.050 |
Why?
|
| 5-Methylcytosine | 1 | 2022 | 117 | 0.050 |
Why?
|
| Hematologic Diseases | 2 | 2012 | 78 | 0.050 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2021 | 88 | 0.050 |
Why?
|
| Kinetics | 4 | 1993 | 1528 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2023 | 471 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 170 | 0.050 |
Why?
|
| COS Cells | 1 | 2000 | 167 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1067 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 309 | 0.050 |
Why?
|
| Appetite | 1 | 2020 | 26 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 71 | 0.040 |
Why?
|
| Hyponatremia | 1 | 2020 | 28 | 0.040 |
Why?
|
| South America | 1 | 2019 | 29 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 273 | 0.040 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 22 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 57 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 73 | 0.040 |
Why?
|
| DNA Primers | 1 | 2000 | 543 | 0.040 |
Why?
|
| Asia | 1 | 2019 | 98 | 0.040 |
Why?
|
| Outpatients | 1 | 2020 | 100 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2020 | 293 | 0.040 |
Why?
|
| Molecular Biology | 1 | 2000 | 89 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 56 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2023 | 9003 | 0.040 |
Why?
|
| North America | 1 | 2019 | 184 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 147 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 65 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2021 | 317 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2020 | 216 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 1999 | 54 | 0.040 |
Why?
|
| Transcription Factor AP-1 | 1 | 1999 | 65 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 321 | 0.040 |
Why?
|
| Global Health | 1 | 2020 | 186 | 0.040 |
Why?
|
| Diarrhea | 1 | 2020 | 182 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 1999 | 85 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2020 | 324 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2008 | 1012 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 1999 | 266 | 0.040 |
Why?
|
| Germ Cells | 2 | 1989 | 130 | 0.040 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2018 | 78 | 0.040 |
Why?
|
| Cell Respiration | 1 | 2017 | 18 | 0.040 |
Why?
|
| Palliative Care | 1 | 2019 | 263 | 0.040 |
Why?
|
| Incidence | 1 | 2022 | 1592 | 0.040 |
Why?
|
| Sex Factors | 1 | 2020 | 1063 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2019 | 995 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2022 | 669 | 0.040 |
Why?
|
| Cell Survival | 2 | 2017 | 982 | 0.040 |
Why?
|
| Base Sequence | 1 | 2000 | 2327 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2019 | 684 | 0.040 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2017 | 85 | 0.040 |
Why?
|
| Thioredoxins | 1 | 2016 | 13 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 78 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 479 | 0.030 |
Why?
|
| Spain | 1 | 2016 | 32 | 0.030 |
Why?
|
| NEDD8 Protein | 1 | 2015 | 1 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2016 | 104 | 0.030 |
Why?
|
| France | 1 | 2015 | 48 | 0.030 |
Why?
|
| Germany | 1 | 2015 | 72 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 374 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2016 | 262 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2017 | 277 | 0.030 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2015 | 37 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1999 | 665 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2015 | 119 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 1108 | 0.030 |
Why?
|
| Exanthema | 1 | 2014 | 39 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2752 | 0.030 |
Why?
|
| Genomics | 2 | 2011 | 761 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 217 | 0.030 |
Why?
|
| Adolescent | 2 | 2016 | 9237 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 337 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2014 | 92 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2016 | 458 | 0.030 |
Why?
|
| Mitochondria | 1 | 2017 | 553 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1837 | 0.030 |
Why?
|
| Neutropenia | 1 | 2014 | 216 | 0.030 |
Why?
|
| Drug Tolerance | 1 | 2012 | 64 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2016 | 459 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 266 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 1867 | 0.030 |
Why?
|
| Cadmium | 1 | 1992 | 28 | 0.030 |
Why?
|
| Second Messenger Systems | 1 | 1991 | 41 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1991 | 258 | 0.020 |
Why?
|
| Demography | 1 | 2012 | 181 | 0.020 |
Why?
|
| Androgen-Binding Protein | 2 | 1988 | 7 | 0.020 |
Why?
|
| Electric Conductivity | 4 | 1992 | 144 | 0.020 |
Why?
|
| Exosome Multienzyme Ribonuclease Complex | 1 | 2011 | 4 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2012 | 111 | 0.020 |
Why?
|
| Bucladesine | 3 | 1991 | 13 | 0.020 |
Why?
|
| Oncogenes | 1 | 2011 | 92 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 2011 | 119 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 1991 | 274 | 0.020 |
Why?
|
| Ribonucleases | 1 | 2011 | 93 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2011 | 92 | 0.020 |
Why?
|
| Follicular Fluid | 1 | 1990 | 10 | 0.020 |
Why?
|
| CpG Islands | 1 | 2011 | 157 | 0.020 |
Why?
|
| Sensation Disorders | 1 | 2010 | 24 | 0.020 |
Why?
|
| Feedback | 1 | 1990 | 134 | 0.020 |
Why?
|
| Methylation | 1 | 2011 | 268 | 0.020 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2011 | 146 | 0.020 |
Why?
|
| Pituitary Hormone-Releasing Hormones | 1 | 1989 | 9 | 0.020 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2011 | 111 | 0.020 |
Why?
|
| Perfusion | 1 | 1990 | 235 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2011 | 529 | 0.020 |
Why?
|
| Osteogenesis | 1 | 2011 | 255 | 0.020 |
Why?
|
| Exons | 1 | 2011 | 451 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1990 | 996 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 105 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2011 | 388 | 0.020 |
Why?
|
| Histones | 1 | 2011 | 329 | 0.020 |
Why?
|
| Homeostasis | 1 | 2011 | 413 | 0.020 |
Why?
|
| DNA Repair | 1 | 2011 | 362 | 0.020 |
Why?
|
| Swine | 1 | 1990 | 581 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1989 | 164 | 0.020 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2008 | 12 | 0.020 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2008 | 18 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2008 | 65 | 0.020 |
Why?
|
| Erythropoietin | 1 | 2008 | 88 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2011 | 887 | 0.020 |
Why?
|
| Physician's Role | 1 | 2010 | 177 | 0.020 |
Why?
|
| E2F1 Transcription Factor | 1 | 2007 | 13 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1989 | 200 | 0.020 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2008 | 132 | 0.020 |
Why?
|
| Chromosomes, Human, X | 1 | 2008 | 55 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2008 | 109 | 0.020 |
Why?
|
| Melanocytes | 1 | 2007 | 57 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2011 | 465 | 0.020 |
Why?
|
| Drug Design | 1 | 2007 | 125 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 2062 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 556 | 0.020 |
Why?
|
| Genitalia, Male | 1 | 1986 | 24 | 0.020 |
Why?
|
| Risk | 1 | 2008 | 657 | 0.020 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 1986 | 44 | 0.020 |
Why?
|
| Pituitary-Adrenal System | 1 | 1986 | 64 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2011 | 1296 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 155 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2007 | 291 | 0.020 |
Why?
|
| RNA Interference | 1 | 2007 | 376 | 0.020 |
Why?
|
| Epithelium | 3 | 1992 | 325 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 3027 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 1157 | 0.020 |
Why?
|
| Leydig Cells | 1 | 1985 | 11 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2008 | 432 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2008 | 250 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2008 | 228 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 988 | 0.020 |
Why?
|
| Reproduction | 1 | 1986 | 199 | 0.020 |
Why?
|
| Binding Sites | 1 | 2007 | 1117 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2007 | 412 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 1993 | 1975 | 0.020 |
Why?
|
| Logistic Models | 1 | 2008 | 1212 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 6288 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2007 | 956 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 975 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 2002 | 51 | 0.010 |
Why?
|
| Medication Errors | 1 | 2002 | 39 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2002 | 287 | 0.010 |
Why?
|
| Cell Separation | 1 | 1981 | 198 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1981 | 284 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2008 | 2399 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 1999 | 33 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1981 | 599 | 0.010 |
Why?
|
| Culture Media | 2 | 1990 | 147 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1999 | 412 | 0.010 |
Why?
|
| Cell Division | 1 | 1999 | 696 | 0.010 |
Why?
|
| Pulsatile Flow | 1 | 1997 | 50 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1999 | 565 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1999 | 447 | 0.010 |
Why?
|
| Phosphorylation | 1 | 1999 | 1130 | 0.010 |
Why?
|
| Gene Expression | 1 | 1999 | 1310 | 0.010 |
Why?
|
| Ovariectomy | 1 | 1993 | 81 | 0.010 |
Why?
|
| Orchiectomy | 1 | 1993 | 72 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 1999 | 1241 | 0.010 |
Why?
|
| Estradiol | 1 | 1993 | 250 | 0.010 |
Why?
|
| Cadmium Chloride | 1 | 1992 | 12 | 0.010 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 1991 | 16 | 0.010 |
Why?
|
| Cholera Toxin | 1 | 1991 | 21 | 0.010 |
Why?
|
| Toxicology | 1 | 1992 | 16 | 0.010 |
Why?
|
| Colforsin | 1 | 1991 | 74 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1991 | 137 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 1991 | 198 | 0.010 |
Why?
|
| Micropore Filters | 1 | 1990 | 2 | 0.010 |
Why?
|
| Electrophysiology | 1 | 1991 | 403 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1993 | 1237 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 1990 | 120 | 0.010 |
Why?
|
| Temperature | 1 | 1991 | 400 | 0.010 |
Why?
|
| Spermatids | 1 | 1989 | 5 | 0.010 |
Why?
|
| Spermatocytes | 1 | 1989 | 7 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1989 | 112 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1989 | 155 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1987 | 91 | 0.000 |
Why?
|
| Injections, Intraventricular | 1 | 1986 | 19 | 0.000 |
Why?
|
| Adrenal Glands | 1 | 1986 | 77 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1987 | 510 | 0.000 |
Why?
|
| DNA | 1 | 1992 | 1307 | 0.000 |
Why?
|
| Organ Size | 1 | 1986 | 369 | 0.000 |
Why?
|
| Body Weight | 1 | 1986 | 452 | 0.000 |
Why?
|
| Models, Biological | 1 | 1992 | 1763 | 0.000 |
Why?
|